A detailed history of Amalgamated Bank transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 1,676 shares of INZY stock, worth $2,664. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,676
Previous 1,676 -0.0%
Holding current value
$2,664
Previous $7,000 28.57%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$4.33 - $7.31 $2,316 - $3,910
535 Added 46.89%
1,676 $7,000
Q1 2024

Apr 23, 2024

SELL
$4.14 - $7.66 $7,497 - $13,872
-1,811 Reduced 61.35%
1,141 $9,000
Q4 2023

Feb 06, 2024

SELL
$2.71 - $4.5 $921 - $1,530
-340 Reduced 10.33%
2,952 $13,000
Q2 2023

Aug 11, 2023

BUY
$4.93 - $6.74 $16,229 - $22,188
3,292 New
3,292 $18,000
Q2 2022

Aug 15, 2022

SELL
$3.2 - $5.96 $5,542 - $10,322
-1,732 Closed
0 $0
Q1 2022

Jun 30, 2022

BUY
$3.87 - $7.55 $6,702 - $13,076
1,732 New
1,732 $7,000

Others Institutions Holding INZY

About Inozyme Pharma, Inc.


  • Ticker INZY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,145,700
  • Market Cap $63.8M
  • Description
  • Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...
More about INZY
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.